Leslie Thompson - Publications

University of California, Irvine, Irvine, CA 
Huntington's Disease

67 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Ochaba J, Monteys AM, O'Rourke JG, Reidling JC, Steffan JS, Davidson BL, Thompson LM. PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron. PMID 27146268 DOI: 10.1016/j.neuron.2016.03.016  0.32
2015 Liu KY, Shyu YC, Barbaro BA, Lin YT, Chern Y, Thompson LM, James Shen CK, Marsh JL. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. Human Molecular Genetics. 24: 1602-16. PMID 25398943 DOI: 10.1093/hmg/ddu574  0.32
2014 Miller S, Hill Della Puppa G, Reidling J, Marcora E, Thompson LM, Treanor J. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease. Journal of Huntington's Disease. 3: 333-41. PMID 25575954 DOI: 10.3233/JHD-140129  0.32
2014 Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, Mao K, Lau AL, Yeung SY, Humbert S, Saudou F, Klionsky DJ, Finkbeiner S, Zeitlin SO, Marsh JL, ... ... Thompson LM, et al. Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proceedings of the National Academy of Sciences of the United States of America. 111: 16889-94. PMID 25385587 DOI: 10.1073/pnas.1420103111  0.32
2014 Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ, Thompson LM. Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer. Plos One. 9: e86470. PMID 24466111 DOI: 10.1371/journal.pone.0086470  0.32
2014 Mattis VB, Wakeman DR, Tom C, Dodiya HB, Yeung SY, Tran AH, Bernau K, Ornelas L, Sahabian A, Reidling J, Sareen D, Thompson LM, Kordower JH, Svendsen CN. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Experimental Neurology. 254: 90-8. PMID 24440640 DOI: 10.1016/j.expneurol.2014.01.007  0.32
2013 Baxa M, Hruska-Plochan M, Juhas S, Vodicka P, Pavlok A, Juhasova J, Miyanohara A, Nejime T, Klima J, Macakova M, Marsala S, Weiss A, Kubickova S, Musilova P, Vrtel R, ... ... Thompson LM, et al. A transgenic minipig model of Huntington's Disease. Journal of Huntington's Disease. 2: 47-68. PMID 25063429 DOI: 10.3233/JHD-130001  0.32
2013 Leavitt BR, Thompson LM. We are pleased to introduce this next volume of the Journal of Huntington's Disease. Introduction. Journal of Huntington's Disease. 2: 1. PMID 25057106 DOI: 10.3233/JHD-130003  0.32
2013 Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, ... ... Thompson LM, et al. Targeting H3K4 trimethylation in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E3027-36. PMID 23872847 DOI: 10.1073/pnas.1311323110  0.32
2013 O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, ... ... Thompson LM, et al. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Reports. 4: 362-75. PMID 23871671 DOI: 10.1016/j.celrep.2013.06.034  0.32
2013 Sontag EM, Joachimiak LA, Tan Z, Tomlinson A, Housman DE, Glabe CG, Potkin SG, Frydman J, Thompson LM. Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 110: 3077-82. PMID 23365139 DOI: 10.1073/pnas.1222663110  0.32
2012 Leavitt BR, Thompson LM. Journal of Huntington's Disease. Journal of Huntington's Disease. 1: 1. PMID 25056612 DOI: 10.3233/JHD-2012-120001  0.32
2012 Sontag EM, Lotz GP, Yang G, Sontag CJ, Cummings BJ, Glabe CG, Muchowski PJ, Thompson LM. Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. Journal of Huntington's Disease. 1: 127-40. PMID 24086178 DOI: 10.3233/JHD-2012-129004  0.32
2012 Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. Journal of Huntington's Disease. 1: 221-41. PMID 23833693 DOI: 10.3233/JHD-129005  0.32
2012 Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C, Marsh JL, Muchowski PJ, Thompson LM. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 11109-19. PMID 22875942 DOI: 10.1523/JNEUROSCI.0895-12.2012  0.32
2012 Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, ... Thompson LM, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiology of Disease. 46: 351-61. PMID 22590724 DOI: 10.1016/j.nbd.2012.01.016  0.32
2012 Pitts A, Dailey K, Newington JT, Chien A, Arseneault R, Cann T, Thompson LM, Cumming RC. Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin. The Journal of Biological Chemistry. 287: 22717-29. PMID 22577145 DOI: 10.1074/jbc.M111.334565  0.32
2012 Bodai L, Pallos J, Thompson LM, Marsh JL. Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease. Neuro-Degenerative Diseases. 9: 104-6. PMID 21912091 DOI: 10.1159/000330505  0.32
2011 Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, ... ... Thompson LM, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nature Chemical Biology. 7: 925-34. PMID 22037470 DOI: 10.1038/nchembio.694  0.32
2011 Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 6858-70. PMID 21543616 DOI: 10.1523/JNEUROSCI.0710-11.2011  0.32
2010 Lotz GP, Legleiter J, Aron R, Mitchell EJ, Huang SY, Ng C, Glabe C, Thompson LM, Muchowski PJ. Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. The Journal of Biological Chemistry. 285: 38183-93. PMID 20864533 DOI: 10.1074/jbc.M110.160218  0.32
2010 McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, ... ... Thompson LM, et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. Embo Molecular Medicine. 2: 349-70. PMID 20665636 DOI: 10.1002/emmm.201000084  0.32
2010 Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, ... ... Thompson LM, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 7927-32. PMID 20378838 DOI: 10.1073/pnas.1002924107  0.32
2010 Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M, Thompson LM, Muchowski PJ. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. The Journal of Biological Chemistry. 285: 14777-90. PMID 20220138 DOI: 10.1074/jbc.M109.093708  0.32
2009 Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron. 64: 828-40. PMID 20064390 DOI: 10.1016/j.neuron.2009.11.020  0.32
2009 Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of Cell Biology. 187: 1083-99. PMID 20026656 DOI: 10.1083/jcb.200909067  0.32
2009 Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D, Purcell JM, Menhaji K, Zhu YZ, Green K, Laferla F, Huang L, Thompson LM, Marsh JL. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. The Journal of Biological Chemistry. 284: 29427-36. PMID 19710014 DOI: 10.1074/jbc.M109.013193  0.32
2009 Salazar L, Kashiwada T, Krejci P, Muchowski P, Donoghue D, Wilcox WR, Thompson LM. A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells. Human Molecular Genetics. 18: 1951-61. PMID 19286672 DOI: 10.1093/hmg/ddp116  0.32
2009 Marsh JL, Lukacsovich T, Thompson LM. Animal models of polyglutamine diseases and therapeutic approaches. The Journal of Biological Chemistry. 284: 7431-5. PMID 18957429 DOI: 10.1074/jbc.R800065200  0.32
2009 Krejci P, Prochazkova J, Bryja V, Jelinkova P, Pejchalova K, Kozubik A, Thompson LM, Wilcox WR. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cellular Signalling. 21: 151-60. PMID 18950705 DOI: 10.1016/j.cellsig.2008.10.006  0.32
2008 Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM, Bryja V, Kozubik A, Wilcox WR. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. Plos One. 3: e3961. PMID 19088846 DOI: 10.1371/journal.pone.0003961  0.32
2008 Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 11500-10. PMID 18987186 DOI: 10.1523/JNEUROSCI.3203-08.2008  0.32
2008 Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Reviews. Drug Discovery. 7: 854-68. PMID 18827828 DOI: 10.1038/nrd2681  0.32
2008 Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Human Molecular Genetics. 17: 3767-75. PMID 18762557 DOI: 10.1093/hmg/ddn273  0.32
2008 Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Molecular and Cellular Neurosciences. 39: 8-20. PMID 18602275 DOI: 10.1016/j.mcn.2008.04.007  0.32
2008 Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Molecular and Cellular Neurosciences. 39: 1-7. PMID 18571429 DOI: 10.1016/j.mcn.2008.04.012  0.32
2008 Thompson LM. Neurodegeneration: a question of balance. Nature. 452: 707-8. PMID 18401401 DOI: 10.1038/452707a  0.32
2008 Krejci P, Salazar L, Goodridge HS, Kashiwada TA, Schibler MJ, Jelinkova P, Thompson LM, Wilcox WR. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. Journal of Cell Science. 121: 272-81. PMID 18198189 DOI: 10.1242/jcs.017160  0.32
2008 McLin JP, Thompson LM, Lusis AJ, Davis RC, Steward O. Genes on distal chromosome 18 determine vulnerability to excitotoxic neurodegeneration following status epilepticus, but not striatal neurodegeneration induced by quinolinic acid. Neurobiology of Disease. 29: 391-9. PMID 17996456 DOI: 10.1016/j.nbd.2007.10.002  0.32
2007 Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Thompson LM, Wilcox WR. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. The Journal of Biological Chemistry. 282: 2929-36. PMID 17145761 DOI: 10.1074/jbc.M606144200  0.32
2007 Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Human Molecular Genetics. 16: 61-77. PMID 17135277 DOI: 10.1093/hmg/ddl440  0.32
2006 McLin JP, Thompson LM, Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. The European Journal of Neuroscience. 24: 3134-40. PMID 17156374 DOI: 10.1111/j.1460-9568.2006.05198.x  0.32
2006 Ross CA, Thompson LM. Transcription meets metabolism in neurodegeneration. Nature Medicine. 12: 1239-41. PMID 17088887 DOI: 10.1038/nm1106-1239  0.32
2006 Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron. 52: 169-78. PMID 17015234 DOI: 10.1016/j.neuron.2006.09.025  0.32
2006 Slepko N, Bhattacharyya AM, Jackson GR, Steffan JS, Marsh JL, Thompson LM, Wetzel R. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proceedings of the National Academy of Sciences of the United States of America. 103: 14367-72. PMID 16980414 DOI: 10.1073/pnas.0602348103  0.32
2006 Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, Legleiter J, Marsh JL, Thompson LM, Lindquist S, Muchowski PJ, Wanker EE. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Human Molecular Genetics. 15: 2743-51. PMID 16893904 DOI: 10.1093/hmg/ddl210  0.32
2006 Desai UA, Pallos J, Ma AA, Stockwell BR, Thompson LM, Marsh JL, Diamond MI. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Human Molecular Genetics. 15: 2114-24. PMID 16720620 DOI: 10.1093/hmg/ddl135  0.32
2006 Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Human Molecular Genetics. 15: 273-85. PMID 16330479 DOI: 10.1093/hmg/ddi443  0.32
2005 Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proceedings of the National Academy of Sciences of the United States of America. 102: 11563-8. PMID 16061794 DOI: 10.1073/pnas.0505321102  0.32
2005 Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA, Thompson LM. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells Human Molecular Genetics. 14: 1529-1538. PMID 15843401 DOI: 10.1093/hmg/ddi161  0.32
2005 Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 102: 3777-81. PMID 15716359 DOI: 10.1073/pnas.0500055102  0.32
2005 Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America. 102: 892-7. PMID 15642944 DOI: 10.1073/pnas.0408936102  0.32
2004 Marsh JL, Thompson LM. Can flies help humans treat neurodegenerative diseases? Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 26: 485-96. PMID 15112229 DOI: 10.1002/bies.20029  0.32
2004 Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL. SUMO modification of Huntingtin and Huntington's disease pathology. Science (New York, N.Y.). 304: 100-4. PMID 15064418 DOI: 10.1126/science.1092194  0.32
2004 Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayán J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, ... ... Thompson LM, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America. 101: 3498-503. PMID 14993615 DOI: 10.1073/pnas.0308679101  0.32
2003 Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiology of Disease. 14: 624-36. PMID 14678777 DOI: 10.1016/j.nbd.2003.08.024  0.32
2003 Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, Marsh JL, Diamond MI. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 40: 685-94. PMID 14622574 DOI: 10.1016/S0896-6273(03)00697-4  0.32
2003 Qin ZH, Wang Y, Kegel KB, Kazantsev A, Apostol BL, Thompson LM, Yoder J, Aronin N, DiFiglia M. Autophagy regulates the processing of amino terminal huntingtin fragments. Human Molecular Genetics. 12: 3231-44. PMID 14570716 DOI: 10.1093/hmg/ddg346  0.32
2003 Thompson LM. An expanded role for wild-type huntingtin in neuronal transcription. Nature Genetics. 35: 13-4. PMID 12947403 DOI: 10.1038/ng0903-13  0.32
2003 Marsh JL, Pallos J, Thompson LM. Fly models of Huntington's disease. Human Molecular Genetics. 12: R187-93. PMID 12925571 DOI: 10.1093/hmg/ddg271  0.32
2003 Thompson LM, Marsh JL. Invertebrate models of neurologic disease: insights into pathogenesis and therapy. Current Neurology and Neuroscience Reports. 3: 442-8. PMID 12914688  0.32
2003 Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, Slepko N, Bear JE, Gertler FB, Hersch S, Housman DE, Marsh JL, Thompson LM. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 100: 5950-5. PMID 12730384 DOI: 10.1073/pnas.2628045100  0.32
2003 Steffan JS, Thompson LM. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opinion On Therapeutic Targets. 7: 201-13. PMID 12667098 DOI: 10.1517/14728222.7.2.201  0.32
2003 Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2041-6. PMID 12576549 DOI: 10.1073/pnas.0437870100  0.32
2002 Toneff T, Mende-Mueller L, Wu Y, Hwang SR, Bundey R, Thompson LM, Chesselet MF, Hook V. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. Journal of Neurochemistry. 82: 84-92. PMID 12091468 DOI: 10.1046/j.1471-4159.2002.00940.x  0.32
2002 Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, Zhu YZ, Gertler FB, Housman DE, Marsh JL, Thompson LM. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nature Genetics. 30: 367-76. PMID 11925563 DOI: 10.1038/ng864  0.32
2002 Peters PJ, Ning K, Palacios F, Boshans RL, Kazantsev A, Thompson LM, Woodman B, Bates GP, D'Souza-Schorey C. Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nature Cell Biology. 4: 240-5. PMID 11854752 DOI: 10.1038/ncb761  0.32
Show low-probability matches.